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sis. were not associated with the incidence of left atrial appendage thrombus. 
Conclusions: Maintenance hemodialysis patients have left atrial appendage thrombus at 
an unexpectedly high Incidence. The chronic use of antiplatelet drugs and the concomi- 
tant presence of diabetes mellltus and a low hematocrit may be Involved in left atrial 
appendage thrombus form&on. 
1008-i 30 Comparison of Echocardiographic Indices of Right 
Ventricular Obstruction in Pulmonary Embolism 
Nicolas Mansencal, Thierry Joseph, Antoine Vieillard-Baron. Salah D. Qanadli, Fran~o~s 
Jardin. Pascal Lacombe, Gutllaume Jondeau, Olivier Dubourg, H&pita1 Ambrolse Par& 
Boulogne. France 
Background: Different echocardiographlc parameters have been described in pulmonary 
embolism (PE). The ouroose of this studv was to determine the most accurate echocar- 
dlographic index of right ventricular obstruction in acute PE. 
Methods: Fiftv-seven consecutive oatients (mean aae 56 * 17 vears) oresentlno with PE 
I  ,  , .  
quantified by angiographic Miller index were studied. Following echocardiographic 
parameters were systematically assessed: 1) right to left ventricular end-dlastollc diame- 
ter ratlo (RVEDD/LVEDD) in parasternal long-axis view, 2) right to left ventricular end- 
diastolic area ratio (RVEDAILVEDA) in apical 4-chamber view, 3) systolic pulmonary 
arterial pressure @PAP) using CW Doppler. 
Results: The correlations between echocardiography and Miller Index were 0.52 for the 
AVEDD/LVEDD, 0.72 for the RVEDA/LVEDA and 0.52 for SPAP. Using Miller index 
higher than 40% to define massw PE with echocardiographic disorders, the cut-off val- 
ues of the RVEDD/LVEDD, the RVEDA’LVEDA and SPAP that yielded the highest dis- 
cnminating power were 0.5, 0.6 and 35 mmHg respectively, according to ROC curves. 
Echocardiographlc ROC curves analysis showed that the RVEDAILVEDA was the more 
accurate indicator of right ventricular obstruction. 
Conclusion: This echocardiographic study suggests that the right to left ventricular end- 
diastolic ratio using apical four-chamber view is the most accurate echocardiographic 
parameter of right ventriculal obstruction in acute PE. with a ratio higher than 0.6. 
1008-i 31 Bosentan Increases Warfarin Dosing Requirements in 
Pulmonary Hypertension 
Matthew P~ncus, Carolyn Corngan, Peter Macdonald. Christouher S. Havward, Anne 
Keogh, St. Vincent’s Hospital, Sydney, Australia 
Background: Bosentan is the first oral agent to have proven effectiveness in pulmonary 
arterial hypertension. Warfarin also has proven benefits and is used in most patients with 
this condition. Data from a trial in healthy volunteers have suggested that bosentan can 
reduce prothrombin time in those taking warfar~n. This is the first study examining the 
effect of bosentan on the International Norm&sing Ratlo (INR) in any patient population. 
Methods: A retrospective observational study was performed of 19 wadarinised patients 
wth pulmonary hypertension who had been enrolled in an open label bosentan study. 10 
of the patients had primary pulmonary hypertension, 4 had chronic thromboembollc pul- 
monary hypertension, 3 had scleroderma and 2 had systemic lupus erythematosis. Their 
mean age was 40 years. The patients had their INR and warlarin dose recorded at base- 
line, after a month of bosentan at a dose of 62.5 mg twice daily, and after an additional 
month at a dose of 125 mg twice daily.Warfar!n doses were adjusted at the discretion of 
the patients’ general practitioners with a target range of 2.3. 
Results: There was an increase in the mean wadarin dose from 3.6 (SD 1.4) to 4.4 (SD 
1.5) after a month on the low bosentan dose and a further increase to 4.6 (SD 1.5) after a 
month on the higher dose. This increase was statistically significant (p<O.Ol). The corre- 
spondmg INRs were 2.5 at baseline, 2.6 after 1 month and 2.5 after 2 months. These 
were not significantly different. 
Conclusion: When warfarinised patients with pulmonary hypertension are starled on 
bosentan, they require a higher dose of waiiarin to maintain a steady INR. 
1008-l 32 The Utility of Sildenafil in Infants With Pulmonary 
Hypertension 
P. V. Suresh A. Varma, R. Sharma, C. John, Sunita Maheshwari, Narayana -I 
Hrudayalaya, Bangalore, India 
Background: The treatment of pulmonary artery hypertension (PAH) has been limited by 
the paucity of effective and affordable oral therapy. The use of sildenafil in adults with 
PAH has been reported. However, its efficacy in the pediatnc population has not been 
fully evaluated. We used It as a last resort in 3 infants with pulmonary hypertension and 
the results are reported. 
Methods: Infants with PAH unresponsive to conventional therapy available at our center 
were considered for sildenafil therapy. Parental consent was obtained in accordance with 
the hospital protocol for Investigational drugs. The clinical status and echocardiographic 
indicators of PAH such as tricuspid regurgitation (TR) jet gradient and the direction of the 
patent ductus arteriosus (PDA) were assessed. As we were using an investigational drug 
as a ‘last-ditch’ effort, cardiac catheterization data was not obtained. Sildenafil was 
started and echo evaluation repeated at 24 hours, 46 hours and 1 week. 
Results: Between March to August 2002, 3 infants at our institution had severe PAH 
requiring therapeutic intervention. The age range was 15 days to 9 months and weight 
was 2.5 to 6.5 kg. The diagnoses included a postoperative PDA ligation (n=l) and 2 
infants with persistent primary pulmonary hypertension with no identifiable cardiac 
cause. In 2 infants the TR jet gradient decreased from 75.60 to 20-30 mmHg within 24 
hours of starting sildenafil, and the patients were rapidly weaned off the ventilator and 
oxygen. In the 9 month old no response was noted initially or at 1 week. 
Conclusion: Oral sildenafil appears to be especially effective in neonates with pulmonary 
hypertension. If it works, the effect appears to be dramatic and occurs within 24-46 
hours. Further prospective trials to assess its effect, and decide on dosing schedules, are 
needed. 
1008-l 33 Survival After Diagnosis of Primary Pulmonary 
Hypertension: Single Center Experience With 
Transplantation and Preoperative Therapy With 
Prostacyclin Analogues 
Michael Dandel Dagmar Kemper, Yuguo Weng, Sead Mulahasanovic, Hans B. 
Lehmkuhl, Bernhard Schulz, Martin Bettmann, Susanne Kapell, Heidrun Bbttcher, 
Manfred Hummel, Roland Hetzer, Deutsches Herzzentrum Berlin, Berlin, Germany 
Background: Without treatment, patients with primary pulmonary hypertension (PPH) 
survive less than 3 years after diagnosis. Our study summarized over 11 years clinical 
experience in PPH therapy. 
Methods: We reviewed our institution’s experience with both transplantation (TX) and 
preoperative prostanoid therapy. The analysis included all PPH patients (56 women, 27 
men) referred by our institution for TX between 1991 and 2002. TX was performed in 36 
of these patients (21 heart-lung and 15 double-lung TX). Since 1996 we used a stepwise 
therapeutic regimen which included beraprost tablets or iloprost inhalation !n the earlier 
stages of the disease and intravenous iloprost infusion in NYHA class IV patbents. 
Results: The actuarial survival since diagnosis for all 85 evaluated patients was 90.5% at 
1 year, 69.4% at 3 years, 62.5% at 10 years, and the mean suwival time since diagnosis 
was 138 * 17 months. Of these patients, only 15 underwent neither vasodilator therapy 
with prostanoids (for various reasons) nor transplantation (8 patients died before TX, 7 
are still on the waiting ltst). The other 70 were treated with prostanoids or with transplan- 
tation or with both. The actuarial suwival after PPH dtagnosis in this group reached 
74.1% at 3 years and 66.7% at 10 years. The 3 year actuarial survival since diagnosis 
was 76.4% in patients treated preoperatively with prostanolds and 56.25% in those with- 
out prostanoids. The mortality rate on the waiting list for TX was 11.5% in the prostanoid 
group and 26.1% in the group without prostanoid treatment. The actuarial post-transplant 
suw~val was 44.5% at 5 years and 42.9% at 8 years. At the present time, 27 patients are 
being treated with prostanoids. Listing for transplantation could be postponed during this 
treatment of 25.2 f 12.6 months duration in 26 patients, although the mean time since 
diagnosis reached already 56.0 254.4 months. 
Conclusions: Since use of prostanolds increases the 3.year actuarial SUIVIV~I after PPH 
diagnosis and reduces the mortality rate on the waiting list, it is an effective bridging-to- 
transplant therapy. Transplantation in combination with prior prostanoid administration 
provides important su~~val benefits for PPH patients. 
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1009-117 Clopidogrel Nonresponders Discovered During Point- 
of-Care Platelet Aggregation Testing 
Wet C. Lau Charlene J. New. Paul B. Watkins, David G. Carville, Kirk E. Guyer, Eric R. 
Bates, University of Michigan Health System, Ann Arbor, MI. Indiana Unwersity, South 
Bend, IN 
Background:The phenomenon of aspirin resistance has recently been recognized. Dur- 
ing the course of determlning that cytochrome P450 (CYP) 3A4 is the primary catalyst for 
the metabolic activation of the prodrug clopidogrel, it was obsewed that the effectiveness 
of a loading dose of clopidogrel varied I” healthy volunteers. 
